Polycystic ovary syndrome (PCOS) affects 5–20% of women of reproductive age worldwide.
The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic …

Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as
reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected …

Objective: The aim was to formulate practice guidelines for the diagnosis and treatment of
polycystic ovary syndrome (PCOS). Participants: An Endocrine Society-appointed Task …

OBJECTIVE: To review all available data and recommend a definition for polycystic ovary
syndrome (PCOS) based on published peer-reviewed data, whether already in use or not, to …

OBJECTIVE: To perform a review and metaanalysis of the studies evaluating the status of
serum inflammatory markers in women with polycystic ovary syndrome (PCOS). DESIGN …

Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2
diabetes mellitus. Because many women with polycystic ovary syndrome (PCOS) are insulin …

Adiponectin, the most abundant protein secreted by white adipose tissue, is known for its
involvement in obesity-related disorders such as insulin resistance, type 2 diabetes mellitus …

Dyslipidemia is a very common metabolic abnormality in women with polycystic ovary
syndrome (PCOS). Insulin resistance is a key pathophysiology of PCOS, thus dyslipidemia …

Developmental origins of adult disease (DoHAD) refers to critical gestational ages during
human fetal development and beyond when the endocrine-metabolic status of the mother …

Androgen excess (hyperandrogenism) is a common endocrine disorder affecting women of
reproductive age. The potential causes of androgen excess in women include polycystic …